Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer.
PMID 15199385 · PMC2364749 · British journal of cancer · 2004 · 7 claims · 7 setups
Six serum protein spots (~40 kDa, pI 5.9–6.6) significantly overexpressed in grade 1, 2 and 3 ovarian cancer patients were identified by MALDI-TOFMS and n-ESIQ(q)TOFMS as isoforms of haptoglobin-1 precursor (HAP1)
-
Has reproduction · 75
Identification and analysis of genes associated with epithelial ovarian cancer by integrated bioinformatics methods.
PMID 34143800 · PMC8213194 · PloS one · 2021 · 7 claims · 6 setups
306 overlapping DEGs (265 up-regulated, 41 down-regulated) were identified across three independent GEO datasets in EOC vs normal ovarian tissue.
-
Full-text index only
Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains.
PMID 18560578 · PMC2409963 · PloS one · 2008 · 8 claims · 6 setups
Ovarian cancer cells exhibit extensive shedding of extra-cellular domains from cell surface proteins into the extracellular milieu.
-
Full-text index only
Diagnostic proteomics: serum proteomic patterns for the detection of early stage cancers.
PMID 15258335 · PMC3851082 · Disease markers · 2003 · 8 claims · 8 setups
Proteomic pattern analysis of serum mass spectra, without identifying the underlying proteins, can distinguish cancer patients from healthy controls with high sensitivity and specificity.
-
Full-text index only
Proteomics as a tool for biomarker discovery.
PMID 18057524 · PMC3851415 · Disease markers · 2007 · 8 claims · 7 setups
A useful clinical biomarker must be easily attainable, have adequate sensitivity, have adequate specificity, and lead to patient benefit through intervention
-
Full-text index only
Analysis of the TGF beta functional pathway in epithelial ovarian carcinoma.
PMID 11531253 · PMC2364123 · British journal of cancer · 2001 · 6 claims · 6 setups
IGFIIR, TGFβ1 and TGFβRII are proposed to function as a unit in the TGFβ growth inhibitory pathway
-
Full-text index only
Fingerprinting cancer development.
PMID 14694892 · PMC1241638 · Environmental health perspectives · 2003 · 8 claims · 6 setups
Protein microarrays can detect phosphoprotein fingerprints that identify early-stage cancer or monitor drug toxicity.
-
Full-text index only
Mutation analysis of the AATF gene in breast cancer families.
PMID 20025740 · PMC2806411 · BMC cancer · 2009 · 6 claims · 6 setups
No AATF sequence alteration identified was predicted to be pathogenic or showed significant association with breast cancer risk
-
Has reproduction · 87
Genetic demultiplexing of pooled single-cell RNA-sequencing samples in cancer facilitates effective experimental design.
PMID 34553212 · PMC8458035 · GigaScience · 2021 · 8 claims · 7 setups
Genetic variation–based demultiplexing tools can be effectively deployed on cancer scRNA-seq tissue using a pooled experimental design, achieving high recall at acceptable precision-recall tradeoffs in both high-CNV (HGSOC) and high-SNV (lung adenocarcinoma) cancers, even with extremely high doublet proportions.
-
Full-text index only
The human homologue of unc-93 maps to chromosome 6q27 - characterisation and analysis in sporadic epithelial ovarian cancer.
PMID 12381271 · PMC134458 · BMC genetics · 2002 · 7 claims · 8 setups
UNC93A maps within the minimal region of allele loss on 6q27 between D6S264 and D6S149, centromeric to D6S149
-
Full-text index only
Pharmacogenomic biomarkers.
PMID 12364812 · PMC3850811 · Disease markers · 2002 · 8 claims · 8 setups
Development of a pharmacogenomic biomarker requires sequential steps: laboratory identification, retrospective confirmation in clinical samples, prospective clinical trial validation, and regulatory approval before patient stratification.
-
Full-text index only
Mutation analysis of the ATR gene in breast and ovarian cancer families.
PMID 15987455 · PMC1175065 · Breast cancer research : BCR · 2005 · 8 claims · 5 setups
ATR mediates the DNA damage response by phosphorylating tumor suppressors such as p53, BRCA1 and CHK1, making it a plausible candidate breast/ovarian cancer susceptibility gene
-
Full-text index only
Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.
PMID 19010816 · PMC6953412 · Molecular cancer research : MCR · 2008 · 8 claims · 8 setups
Activating RAS-MAPK pathway mutations are present in >70% of serous LMP tumors versus ~12.5% of serous ovarian carcinomas
-
Full-text index only
Immunohistochemical and proteomic evaluation of nuclear ubiquitous casein and cyclin-dependent kinases substrate in invasive ductal carcinoma of the breast.
PMID 20069058 · PMC2801467 · Journal of biomedicine & biotechnology · 2009 · 7 claims · 5 setups
NUCKS is highly overexpressed in invasive ductal carcinoma (IDC) of the breast compared to matched normal tissue.
-
Full-text index only
Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery.
PMID 19936259 · PMC2775948 · PloS one · 2009 · 8 claims · 8 setups
Integrated proteomic analysis of a cancer mouse model and human cancer cell populations provides an effective approach to identify potential circulating protein biomarkers.
-
Full-text index only
Comparing protein abundance and mRNA expression levels on a genomic scale.
PMID 12952525 · PMC193646 · Genome biology · 2003 · 8 claims · 8 setups
Correlations between mRNA expression and protein abundance are generally poor or limited across most studies reviewed, including in yeast and human cancers
-
Full-text index only
Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy.
PMID 15601541 · PMC3525069 · Human genomics · 2004 · 8 claims · 6 setups
DNA microarray gene expression profiling generates robust molecular classifications for many tumour types (brain, breast, colon, gastric, kidney, leukaemia, lymphoma, lung, melanoma, ovary, prostate, etc.)
-
Full-text index only
New perspectives on an old disease: proteomics in cancer research.
PMID 17472735 · PMC1895992 · Genome biology · 2007 · 8 claims · 8 setups
The HUPO Plasma Proteome Project has catalogued over 3,020 non-redundant gene products (>7,000 proteins/isoforms) in human plasma, many originating from tissues/organs rather than being plasma-intrinsic.
-
Full-text index only
Social and ethical implications of genomics, race, ethnicity, and health inequities.
PMID 19000599 · PMC2892396 · Seminars in oncology nursing · 2008 · 8 claims · 5 setups
Race and ethnicity are increasingly viewed as genetic surrogates for predicting disease risk and treatment response, though directly assessing genomic and environmental factors is more accurate.
-
Full-text index only
A European focus on proteomics.
PMID 15128441 · PMC416463 · Genome biology · 2004 · 8 claims · 8 setups
MALDI-MS and ESI-MS are complementary techniques that identify overlapping but distinct subsets of proteins